Monopar Therapeutics Inc. Announces Pricing of Initial Public Offering
Dec 18, 2019
1 min read
CHICAGO, Dec. 18, 2019 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. today announced that it has priced an initial public offering of 1,111,112 shares of its common stock at $8.00 per share. The shares are expected to begin trading on the Nasdaq Capital Market on December 19, 2019 under the symbol “MNPR.” The offering is expected to close on December 23, 2019, subject to the satisfaction of customary closing conditions. In addition, the underwriters have been granted a 30-day option to purchase up to an additional 166,666 shares.
Traffic Jam 3D is an entertaining puzzle game with an endless stream of exciting levels. I enjoy starting the game every day to face new traffic management problems, which help me improve my thinking abilities and capacity to handle issues swiftly.
Clear and useful coverage of an important milestone for Monopar Therapeutics. Presenting the offering details in a straightforward way makes the announcement easy to follow, especially for readers who want to understand the mechanics of an IPO. I appreciated the concise format, and dentist in etobicoke reminded me that clear communication is valuable in every professional setting, particularly when details matter.
The announcement presents the details of Monopar Therapeutics’ initial public offering in a clear and straightforward way. Including the offering size, pricing, and expected trading information makes the update useful for readers following the company’s development. I recently encountered a similar discussion on https://gocollectiv.com/, where the financial perspective was equally interesting. This post provides helpful context around an important corporate milestone.
At the time of the IPO, Monopar Therapeutics described itself as a clinical-stage biopharmaceutical company developing Slither io therapies intended to improve outcomes for cancer patients.
Congrats to Monopar on reaching this milestone! The $8.00 IPO pricing looks solid, and I'll be following the MNPR ticker on Nasdaq with interest.